No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABBV AbbVie
- 162.930
- -1.630-0.99%
Close May 21 16:00 ET
- 162.790
- -0.140-0.09%
Post 19:47 ET
287.71BMarket Cap48.49P/E (TTM)
165.705High162.500Low3.65MVolume165.370Open164.560Pre Close594.70MTurnover0.21%Turnover Ratio59.90P/E (Static)1.77BShares181.19652wk High35.94P/B287.08BFloat Cap125.84752wk Low5.99Dividend TTM1.76BShs Float181.196Historical High3.68%Div YieldTTM1.95%Amplitude20.362Historical Low163.144Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
These 4 Measures Indicate That AbbVie (NYSE:ABBV) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Teva, Alvotech Launch Biosimilar Against AbbVie's Humira
Express News | NYSE Order Imbalance 57284.0 Shares on Sell Side
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
Express News | NYSE Order Imbalance 280471.0 Shares on Sell Side
Comments
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
3
1
Hello Mooers! ![]()
Recently, there have been signs that World War 3![]()
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. ![]()
In light of this hypothetical situation![]()
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. ![]()
![]()
![]()
Approach One: Buy the winners
Who are the winners?![]()
During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
28
36
$Novo-Nordisk A/S(NVO.US$ & $Eli Lilly and Co(LLY.US$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
4
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$ $GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$ $GlaxoSmithKline(GSK.US$
5
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Xiaobie : how do you read TRIPLE?